20 to 50     : Initial dose 25 mg/day and increase in increments of 25–50 mg/day according to response
10 to 20     : Initial dose 25 mg/day and increase in increments of 25–50 mg/day according to response
<10           : Initial dose 25 mg/day and increase in increments of 25–50 mg/day according to response
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in GFR <10 mL/min
HD                     :Unknown dialysability. Dose as in GFR <10 mL/min
HDF/high flux   :Unknown dialysability. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids
Antibacterials: concentration possibly increased by macrolides – reduce dose of quetiapine
Antidepressants: concentration of tricyclics possibly increased
Anti-epileptics: antagonism of convulsive threshold; metabolism accelerated by carbamazepine and phenytoin
Antifungals: concentration possibly increased by imidazoles and triazoles – reduce quetiapine dose
Antimalarials: manufacturer advises avoid use with artemether and lumefantrine
Antivirals: ritonavir possibly increases concentrationAnxiolytics and hypnotics: enhanced sedative effects
Sibutramine: increased risk of CNS toxicity – avoid concomitant use
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Plasma clearance is reduced by 25% in severe renal impairmentAbsorption is increased by food so it should be taken consistently either with or without food.
